Want to learn more about the biomarkers involved in Alzheimer's disease testing, and how cerebrospinal fluid is collected? Check out our biomarker and specimen collection guides on our Resources page. Developed in partnership with individuals with lived experience with dementia The biomarker testing guides were developed in partnership with participants in the IMPACT-AD study. Participants that chose to have the testing done, as well as participants that supported a friend or

The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific journal! The first method to identify both sporadic and autosomal dominant Alzheimer's disease This is the first method to identify both sporadic AD (by wt-Aβ42 and wt-Aβ40 concentration) and autosomal dominant AD (by identification of pathogenic APP variants) in one anatysis, enabling biomarker testing without a priori knowledge of the genetic

At the 2020 Alzheimer Update, Dr. DeMarco and Dr. Hsiung discuss biomarker testing and therapies for Alzheimer's disease. https://www.ubcalzheimerforum.ca #biomarkers

The IMPACT-AD ("Translating research into practice: Investigating the impact of Alzheimer's disease diagnostics in Canada") Study was awarded funding from Health Canada, Brain Canada, Michael Smith Health Research BC, UBC’s Faculty of Medicine and Djavad Mowafaghian Centre for Brain Health, Women’s Brain Health Initiative, St. Paul’s Foundation. In addition, key collaborators include the Alzheimer Society of Canada and the Canadian Consortium on Neurodegeneration in Aging. Al